stockrowAltimmune, Inc. (ALT) vs Lyell Immunopharma, Inc. (LYEL)
- Altimmune, Inc. ALT 2.06 +4.57%
- Lyell Immunopharma, Inc. LYEL 14.82 −1.20%
Altimmune, Inc. and Lyell Immunopharma, Inc. are both Biotechnology companies. Altimmune, Inc. and Lyell Immunopharma, Inc. are of similar size ($383.2M and $367.6M). Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against −63.4%. Altimmune, Inc. has the higher net margin (0.00% vs −1,701,066.7%) and the higher return on invested capital (−34.3% vs −1,070.8%). Across the 17 metrics below, Altimmune, Inc. leads on 14 and Lyell Immunopharma, Inc. on 3.
Valuation
Profitability
| Metric | ALT | LYEL | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 68.51% |
| Operating margin | 0.00% | (1,783,580.00%) | 0.00% |
| Net margin | 0.00% | (1,701,066.67%) | 0.00% |
| Free cash flow margin | 0.00% | (928,333.33%) | 0.00% |
| Return on equity | (28.87%) | (97.79%) | (51.96%) |
| Return on assets | (25.58%) | (74.85%) | (46.06%) |
| Return on invested capital | (34.30%) | (1,070.83%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack